Journal
THORACIC SURGERY CLINICS
Volume 30, Issue 4, Pages 395-423Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.thorsurg.2020.08.001
Keywords
Mesothelioma; Biomarkers; Asbestos; Prognosis; Diagnosis
Categories
Funding
- EDRN Mesothelioma Biomarker Discovery Laboratory [5U01CA214195-04]
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is an asbestos-related neoplasm that can only be treated successfully when correctly diagnosed and treated early. The asbestos-exposed population is a high-risk group that could benefit from sensitive and specific blood- or tissue-based biomarkers. We review recent work with biomarker development in MPM and literature of the last 20 years on the most promising blood- and tissue-based biomarkers. Proteomic, genomic, and epigenomic platforms are covered. SMRP is the only validated blood-based biomarker with diagnostic, monitoring and prognostic value. To strengthen development and testing of MPM biomarkers, cohorts for validation must be established by enlisting worldwide collaborations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available